What's new

Human medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 2, Status: Authorised

Mar 19, 2025 - 15:03
 0
Human medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 2, Status: Authorised
Read More

Tags:

Previous Article

Fierce Biotech Fundraising Tracker '25: Ampersand raises $65M; Arbor adds $74M

Next Article

A world first: Japan’s new train station to be built in just 6 hours

Related Posts

Human medicines European public assessment report (EPAR): Pregabalin Sandoz, pregabalin, Date of authorisation: 19/06/2015, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 19, 2025  0

Orphan designation: Camostat mesilate Treatment of chronic pancreatitis, 16/01/2025 Positive

Orphan designation: Camostat mesilate Treatment of chro...

Feb 20, 2025  0

Human medicines European public assessment report (EPAR): Skilarence, dimethyl fumarate, Date of authorisation: 23/06/2017, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 17, 2025  0